Palopegteriparatide
Also referenced as: Yorvipath
A sustained-release prodrug delivering PTH(1–34) for adult hypoparathyroidism.
- Evidence grade
- BModerate Human Evidence
Moderate Human Evidence
- Regulatory status
- FDA Approved for Specific Indication
Yorvipath received FDA approval in August 2024 for hypoparathyroidism in adults.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A sustained-release prodrug delivering PTH(1–34) for adult hypoparathyroidism.
Yorvipath received FDA approval in August 2024 for hypoparathyroidism in adults.
It has not been established for acute postsurgical hypoparathyroidism, and replacement use is distinct from anabolic osteoporosis treatment.
Why It's Being Studied
- Hypoparathyroidism
- Calcium regulation
Mechanism of Action
Controlled release of PTH(1–34) supports physiological calcium regulation; it is not full-length PTH(1–84).
Controlled release of PTH(1–34) supports physiological calcium regulation; it is not full-length PTH(1–84). It has not been established for acute postsurgical hypoparathyroidism, and replacement use is distinct from anabolic osteoporosis treatment.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Hypoparathyroidism
- Calcium regulation
- Subcutaneous approved medicine
Evidence Summary
A pivotal randomized trial supported calcium control with independence from active vitamin D and therapeutic calcium supplementation.
Higher tiers carry more weight. Filled tiers have evidence for Palopegteriparatide; tap to read it.
- A pivotal randomized trial supported calcium control with independence from active vitamin D and therapeutic calcium supplementation.
1 cited sources.
- Prescribing label1
Human clinical evidence
- A pivotal randomized trial supported calcium control with independence from active vitamin D and therapeutic calcium supplementation.
Reported Adverse Events in Research
- Serious low or high calcium, orthostatic symptoms and osteosarcoma-risk precautions require monitoring.
Limitations of Current Evidence
- It has not been established for acute postsurgical hypoparathyroidism, and replacement use is distinct from anabolic osteoporosis treatment.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Palopegteriparatide | Trofinetide | |
|---|---|---|
| Evidence grade | B — Moderate Human Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Subcutaneous approved medicine | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Palopegteriparatide — prescribing label